Celcuity Revtorpyk Approved, Stock Down 18%: Piqray Problem

The FDA approved Celcuity’s gedatolisib (Revtorpyk) on July 14, 2026, three days ahead of its PDUFA date. The stock has fallen 18% since. Celcuity closed at $107.58 on July 10. It closed at $88.34 on July 24. That is a $460 million market cap wipeout in two weeks, and the market is telling you something the press release does not.

The science is genuinely strong. The business case is the problem. And the warning sign is sitting right there in Novartis’s declining Piqray sales.

The data: this is not a marginal drug

The VIKTORIA-1 trial (NCT05501886) tested gedatolisib in HR+/HER2- advanced breast cancer after patients had already progressed on CDK4/6 inhibitors and aromatase inhibitors. This is a sick, treatment-resistant population. The results were published in the Journal of Clinical Oncology in March 2026.

For the PIK3CA wild-type cohort, the primary analysis:

• Gedatolisib triplet (gedatolisib + palbociclib + fulvestrant): median PFS 9.3 months vs 2.0 months with fulvestrant alone. Hazard ratio 0.24 (95% CI 0.17-0.35, p<0.0001). That is a 76% reduction in the risk of disease progression or death.
• Gedatolisib doublet (gedatolisib + fulvestrant): median PFS 7.4 months vs 2.0 months. HR 0.33 (95% CI 0.24-0.48, p<0.001). A 67% risk reduction.

A 76% risk reduction in a post-CDK4/6 population is not incremental. That is the kind of number that changes practice. For context, most successful oncology drugs show hazard ratios of 0.5 to 0.7. Gedatolisib’s 0.24 is exceptional.

The PIK3CA mutant cohort was equally impressive. The gedatolisib doublet delivered median PFS of 11.3 months vs 5.6 months with alpelisib plus fulvestrant (HR 0.51, 95% CI 0.33-0.79, descriptive p=0.0013). That is a head-to-head win against the only approved PI3K inhibitor in breast cancer. The ORR was 35.7% with a median duration of response of 24.2 months. More on the alpelisib problem in a moment.

Safety was manageable. Serious adverse events occurred in 10.8% of triplet patients and 9.2% of doublet patients. Treatment discontinuation due to adverse events was 2.3% for the triplet, 3.1% for the doublet, and 0% for fulvestrant. The stomatitis that plagued earlier PI3K inhibitors was mitigated with a prophylactic mouthwash regimen. The discontinuation rates are low by oncology standards. For comparison, Piqray’s discontinuation rate in the SOLAR-1 trial was 21% due to adverse events. Gedatolisib’s 2.3-3.1% rate is a meaningful tolerability advantage.

The mechanism matters here. Gedatolisib is a dual PI3K/mTOR inhibitor. Unlike alpelisib, which targets only PI3K-alpha, gedatolisib binds all class I PI3K isoforms and mTORC1/2. This dual inhibition is why it works in both PIK3CA-mutant and wild-type tumors: it does not depend on a single mutation to drive activity. The drug is delivered intravenously, a commercial disadvantage in outpatient oncology where oral drugs dominate. The efficacy profile may justify the infusion burden.

The “sell the news” is telling you something

Celcuity’s stock fell from $107.58 to $88.34 after approval. The approval day saw 8.75 million shares trade, roughly 5x normal volume. This is not a quiet drift. It is an exit.

The market is pricing in the hard part: commercialization. Celcuity is a 155-person company with zero revenue and a $52.8 million quarterly net loss (Q1 2026, per Polygon financials). Its first commercial product launches into a market where the incumbent is retreating.

Here is the problem: Piqray (alpelisib), Novartis’s PI3K inhibitor, generated $382 million in 2025 revenue, down 15% year-over-year. Novartis attributed the decline to competition across all markets. If the only approved drug in this class is shrinking, what does that tell you about the commercial viability of the class?

Piqray is approved only for PIK3CA-mutated breast cancer. Gedatolisib is approved for PIK3CA wild-type, a population roughly 1.5x larger (about 60% of HR+/HER2- tumors are wild-type vs 40% mutated). Celcuity has a bigger addressable market. But the PI3K inhibitor class has a track record of reimbursement pushback, tolerability issues, and slow adoption. Gedatolisib’s superior data may overcome this. The data certainly supports it. But Celcuity has to prove it at the commercial level, and they have no oncology commercial infrastructure.

Compare this to GSK, which just received approval for Jideytro in ROS1 NSCLC. GSK is a $100 billion pharma company with existing oncology commercial channels. GSK closed a Nuvalent acquisition and had FDA approval within a week. Celcuity has 155 employees in Minneapolis and a diagnostic lab background.

The valuation: pricing in perfection

At $88.34, Celcuity’s market cap is $4.31 billion (per Polygon reference data). For a company with zero revenue, that is a price-to-sales ratio of infinity until launch ramps.

Peak sales estimates for gedatolisib range from $1 billion to $2 billion if the drug captures both wild-type and mutant populations. At $2 billion peak, that is a 2.15x P/S at market cap. Compare to Madrigal Pharmaceuticals, which faces its own PDUFA for resmetirom in MASH. Madrigal trades at roughly $7.2 billion market cap with peak sales estimates of $2-4 billion. That is 1.8-3.6x P/S. Celcuity’s valuation is in the same range, but Madrigal is launching into an empty market with no competition. Celcuity is launching into a market where the existing player is losing share.

BioMarin (BMRN), a proven rare disease commercial operator, trades at $11.4 billion market cap against $2.8 billion in annual revenue. That is roughly 4x P/S, and BioMarin has a diversified portfolio. Celcuity has one drug. The risk concentration is extreme.

What changes the thesis

The clearest bull case is the pending sNDA filing for the PIK3CA mutant population, expected in Q3 2026 per Celcuity’s guidance. If approved for both wild-type and mutant, gedatolisib becomes the first PI3K inhibitor approved across both populations, which would meaningfully expand the addressable market. Two secondary catalysts could add upside: early prescription data showing adoption faster than Piqray’s trajectory, or a partnership or acquisition by a larger oncology company with commercial infrastructure.

The risk factors are equally concrete. Celcuity burned $52.8 million in Q1 2026. At that rate, the company has roughly 12-18 months of runway before needing to raise capital, depending on launch costs. A secondary offering would dilute existing shareholders at the worst possible time. There is also competitive risk from CDK4/6 inhibitor manufacturers moving earlier in the treatment sequence, which could shrink the post-progression market that gedatolisib targets. Pfizer is seeking priority review for Talzenna plus Xtandi in earlier-line prostate cancer and the same dynamic applies in breast cancer: if CDK4/6 inhibitors move earlier, the post-progression population changes. For more on how binary catalysts shape biotech valuations, see our analysis of the pre-approval setup.

There is also pipeline depth risk. Celcuity has VIKTORIA-2 in endocrine-resistant breast cancer and CELC-G-201 in metastatic castration-resistant prostate cancer, both early stage. If gedatolisib fails to commercialize, the pipeline is years from contributing revenue. This is a single-product company with one approved drug. That concentration risk is why the stock is sensitive to every prescription data point and every reimbursement decision.

The verdict

The VIKTORIA-1 data is the real deal. A hazard ratio of 0.24 in a post-CDK4/6 population is exceptional, and the head-to-head win against alpelisib in the mutant cohort is a genuine differentiator. But at $4.3 billion market cap with zero revenue, $52.8 million quarterly burn, and no commercial infrastructure, Celcuity is priced for a flawless launch into a market where the incumbent is shrinking.

I would not buy CELC at $88. The risk-reward is poor until we see prescription data. If the stock pulls back to $65-70 on general market weakness, the risk-reward improves meaningfully. If early prescription data in Q4 2026 shows adoption tracking ahead of Piqray’s launch curve, the stock rerates higher. Until then, the science does not justify the price. Novartis’s $382 million and declining is the number that matters, and it is not a bullish signal.

Source: VIKTORIA-1 trial, Journal of Clinical Oncology | FDA approval announcement